股票代码：300016 股票简称：北陆药业 公告编号：2025-114 北京北陆药业股份有限公司 关于钆布醇注射剂拟中选第十一批全国药品集中采购的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"） 参加了国家组 织药品联合采购办公室（以下简称"联采办"）组织的第十一批全国药品集中 采购投标工作，公司钆布醇注射剂拟中选。现将相关情况公告如下： 二、对公司的影响 公司拟中选产品钆布醇注射剂于 2022 年 4 月、2024 年 4 月分别获得国家 1 中标企业 药品通用名 适应症 申报品规 计价 单位 拟中选价 （元） 拟主供应 省份 北京北陆药业 股份有限公司 钆布醇注射剂 用于诊断，仅供静脉内 给药。全身各部位（包 括颅脑和脊髓）病变的 对比增强磁共振成像 (CE-MRI)检查；对比 增强磁共振血管造影 (CE-MRA)检查。 7.5ml： 4.5354g 瓶 45.84 辽 宁 、 湖 北、广西、 内蒙古、重 庆、宁夏 一、拟中选产品基本情况 药品监督管理局核准签发的《药品注册证书》及《药品补充申请批准通 ...

Core Insights - Northland Pharmaceutical (300016.SZ) released its Q3 2025 report, indicating a total of 52.656 million A-shares held by three institutional investors, accounting for 9.35% of the company's total share capital [1] Institutional Holdings - The total institutional holding percentage decreased by 2.44 percentage points compared to the previous quarter [1] - The institutional investors include Chongqing Three Gorges Paint Co., Ltd., China Resources Yukun Asset Management Co., Ltd., and Guolian Medical Health Mixed A [1] Public Fund Holdings - One public fund, Guolian Medical Health Mixed A, reported a slight decrease in holdings compared to the previous quarter [1] - Ten public funds that did not disclose holdings this quarter include notable names such as PICC Trend Selection Mixed A, Wanji Entrepreneur Board Comprehensive ETF, and Southern CSI 2000 ETF [1] Foreign Investment - Several foreign institutions, including BARCLAYS BANK PLC, MORGAN STANLEY & CO. INTERNATIONAL PLC, and Goldman Sachs LLC, did not disclose their holdings this quarter [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 873 million yuan, representing a year-on-year growth of 19.59% [1] - The net profit attributable to shareholders of the listed company was 44.1769 million yuan, showing a year-on-year increase of 81.10% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 33.6758 million yuan, reflecting a year-on-year growth of 33.53% [1] - Basic earnings per share were reported at 0.087 yuan [1]

Core Viewpoint - Beilu Pharmaceutical (300016) announced that neither the company nor its controlling and wholly-owned subsidiaries have any violations regarding guarantees or overdue guarantees, and there are no external guarantees involved in lawsuits or losses due to guarantee judgments [1] Summary by Categories - **Company Compliance** - The company confirmed no violations in guarantees or overdue guarantees [1] - There are no external guarantees related to lawsuits or losses from guarantee judgments [1]

Group 1 - The core viewpoint of the article highlights that Beijing Beilu Pharmaceutical Co., Ltd. reported significant growth in revenue and net profit for the first three quarters of 2025, with revenue reaching 873 million yuan, a year-on-year increase of 19.59%, and net profit attributable to shareholders amounting to 44.18 million yuan, up 81.10% [1][2] - The growth in net profit is attributed to multiple factors, including the company's ongoing efforts in standardizing products for centralized procurement and actively promoting non-procurement products and overseas market sales, which contributed to stable revenue growth [1] - The completion of the conversion of "Beilu Convertible Bonds" led to reduced interest expenses, positively impacting net profit metrics [1] Group 2 - Beilu Pharmaceutical's subsidiary, Haichang Pharmaceutical, achieved significant progress in research and registration, including the approval of iodinated contrast agents for market entry in various countries, which lays a foundation for expanding domestic and international markets [1] - The company plans to continue its dual-driven strategy of "chemical drugs + traditional Chinese medicine," focusing on both domestic and overseas markets to enhance profitability and overall competitiveness [2]

Core Insights - Beilu Pharmaceutical (300016) reported strong performance in Q3 2025, with revenue reaching 873 million yuan, a year-on-year increase of 19.59%, and net profit attributable to shareholders at 44.18 million yuan, up 81.10% [1] - The growth in net profit was driven by the implementation of centralized procurement products and expansion in non-centralized procurement products and overseas markets [1] - The company plans to raise up to 300 million yuan through a simplified procedure for issuing shares to specific investors, aimed at funding various projects and supplementing working capital [2] Financial Performance - For the first three quarters of 2025, Beilu Pharmaceutical achieved operating revenue of 873 million yuan, a 19.59% increase year-on-year [1] - Net profit attributable to shareholders was 44.18 million yuan, reflecting an 81.10% increase compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 33.68 million yuan, up 33.53% year-on-year [1] Strategic Developments - The company is focusing on a dual-driven strategy of "chemical drugs + traditional Chinese medicine" while enhancing its presence in both domestic and international markets [2] - Significant progress was made by the subsidiary Haichang Pharmaceutical, including the approval of several chemical raw materials and obtaining market access in Korea and India [2] - The funds raised will support the construction of new production lines and enhance the company's operational capabilities [2]

Group 1 - Company announced a guarantee of up to 400 million RMB for its wholly-owned subsidiary, Luzhibao Pharmaceutical, to support the construction of a production project for traditional Chinese medicine and high-end pharmaceutical formulations [1] - The board of directors approved the guarantee at the fifth meeting of the ninth board session held on October 27, 2025, with a guarantee period not exceeding ten years [1] - As of the announcement date, the total amount of guarantees provided by the company to its subsidiaries is not more than 890 million RMB, accounting for no more than 53.37% of the company's audited net assets for 2024 [1] Group 2 - The company's revenue composition for the year 2024 indicates that 98.88% comes from pharmaceutical production, while other business income accounts for 1.12% [1] - The current market capitalization of the company is 4.8 billion RMB [2]

第四条 公司的董事、高级管理人员应当遵守信息披露制度的要求，对公司定期报告及 重大事项履行必要的传递、审核和披露流程。 外部信息使用人管理制度 （2025年修订） 第一条 加强北京北陆药业股份有限公司（以下简称"公司"）定期报告及重大事项在 编制、审议和披露期间的外部信息使用人管理，依据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《深圳 证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《北京北陆药业股份 有限公司章程》（以下简称"《公司章程》"）、《上市公司信息披露管理办法》和《上 市公司监管指引第5号——上市公司内幕信息知情人登记管理制度》等有关规定，制定本制 度。 第二条 本制度的适用范围包括公司及其各部门、全资及控股子公司以及公司的董事、 高级管理人员和其他相关人员，公司对外报送信息涉及的外部单位或个人。 第三条 本制度所指"信息"是指对公司股票及衍生品种的交易价格可能产生重大影响 的尚未公开的信息，包括但不限于定期报告、临时报告、财务数据以及正在策划、编制、 审批和披露期间的重大事项。尚未公开是指公司董事会尚未在中国证券监督管理 ...

年报信息披露重大差错责任追究制度 （2025年修订） 第一章 总则 第一条 为了提高公司的规范运作水平，加强信息披露的真实性、准确性、完整性和及 时性，提高年报信息披露的质量和透明度，加大对年报信息披露责任人的问责力度，根据 《中华人民共和国证券法》、《中华人民共和国会计法》、《上市公司信息披露管理办法》、 《上市公司治理准则》、《公开发行证券的公司信息披露编报规则第15号——财务报告的 一般规定》等相关法律法规及公司章程的规定，结合公司实际情况制定本制度。 公司信息披露内容与格式准则第2号——年度报告的内容与格式》、深圳证券交易所信息披 露指引等规章制度、规范性文件和《公司章程》及其他内部控制制度的规定，存在重大错 误或造成不良影响。 （四）业绩预告与年度报告实际披露业绩存在重大差异且不能提供合理解释的。 （五）业绩快报中的财务数据和指标与相关定期报告的实际数据和指标存在重大差异 且不能提供合理解释的。 第二条 本制度适用于公司的董事、高级管理人员、公司各子（分）公司的负责人、公 司以及各子（分）公司财务部门的工作人员以及与年度报告信息披露工作有关的其他人员 （以上统称"年报信息披露相关人员"）。年报信息披 ...

投资者关系管理制度 （2025年修订） 第一章 总则 第一条 为了加强北京北陆药业股份有限公司（以下简称"公司"）与投资者和潜在投 资者（以下合称"投资者"）之间的信息沟通，完善公司治理结构，切实保护投资者特别是 社会公众投资者的合法权益，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司与投资者关系管理工作指 引》、《深圳证券交易所创业板股票上市规则》（以下简称"《创业板上市规则》"）、《深圳证 券交易所上市公司自律监管指引第 2 号－－创业板上市公司规范运作》等有关法律、法规 和《北京北陆药业股份有限公司章程》（以下简称"《公司章程》"）的规定，结合本公司实 际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流和诉 求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对公司的了解和认同， 以提升公司治理水平和企业整体价值，实现尊重投资者、回报投资者、保护投资者目的的 活动。 第三条 投资者关系管理的目的是： （一）促进公司与投资者之间的良性关系，增进投资者对公司的进一步了解和熟悉； （二）建立 ...